Thor Medical ASA (OSE:TRMED), a supplier of alpha-emitters for precision cancer treatment, announced on Thursday that it has signed a five-year supply agreement with AdvanCell, an Australian radiopharmaceutical company, to deliver Thorium-228.
The deal, valued at approximately NOK100m, follows successful deliveries of Thorium-228 samples from Thor Medical's new pilot facilities to AdvanCell earlier this year.
AdvanCell will use the Thorium-228 to produce Pb-212, a key ingredient in its cancer therapies, including ADVC001, which is currently in Phase I/II clinical trials.
This is Thor Medical's third commercial supply agreement this year.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis